Novavax (WBO:NVAX) Interest Expense : €-15.2 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Novavax Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Novavax's interest expense for the three months ended in Sep. 2024 was € -3.8 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was €-15.2 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Novavax's Operating Income for the three months ended in Sep. 2024 was € -120.8 Mil. Novavax's Interest Expense for the three months ended in Sep. 2024 was € -3.8 Mil. Novavax did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Novavax Interest Expense Historical Data

The historical data trend for Novavax's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Interest Expense Chart

Novavax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-10.97

-12.45

-18.70

-18.77

-13.22

Novavax Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-2.68	-3.78	-3.78	-3.85	-3.82

Novavax Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-15.2 Mil.

Novavax (WBO:NVAX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Novavax's Interest Expense for the three months ended in Sep. 2024 was €-3.8 Mil. Its Operating Income for the three months ended in Sep. 2024 was €-120.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was €201.5 Mil.

Novavax's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Novavax did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Novavax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (WBO:NVAX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

NVAX:USA NVAX:Mexico NVV1:Germany NVV1:Germany NVV1:Germany NVV1:Bulgaria

Address

700 Quince Orchard Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.